التفاصيل البيبلوغرافية
| العنوان: |
Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management. |
| المؤلفون: |
Shi, Yibo1 (AUTHOR), Wang, Hanzhang1,2 (AUTHOR), Golijanin, Borivoj3 (AUTHOR), Amin, Ali4 (AUTHOR), Lee, Joanne4 (AUTHOR), Sikov, Mark5 (AUTHOR), Hyams, Elias3 (AUTHOR), Pareek, Gyan3 (AUTHOR), Carneiro, Benedito A.6 (AUTHOR), Mega, Anthony E.6 (AUTHOR), Lagos, Galina G.6 (AUTHOR), Wang, Lisha7 (AUTHOR), Wang, Zhiping1 (AUTHOR), Cheng, Liang1,4 (AUTHOR) liang_cheng@yahoo.com |
| المصدر: |
Urologic Oncology. May2024, Vol. 42 Issue 5, p144-154. 11p. |
| مصطلحات موضوعية: |
*TUMOR suppressor genes, *MOLECULAR pathology, *CARCINOMA, *PROSTATE, *PROSTATE cancer, *RECOMBINANT DNA |
| مستخلص: |
• PDA, IDC-P and CC-P differ in terms of genetics, prognosis, and response to treatment. • PTEN mutations are frequently present in IDC-P and CC-P. • The clinical benefit may be dependent on the specific HRR gene mutated. • All morphologies other than PAA are not recommended for focal therapy. • PDA, ICD-P and CC-P are particularly associated with poor prognosis compared with PAA. Prostatic acinar adenocarcinoma accounts for approximately 95% of prostate cancer (CaP) cases. The remaining 5% of histologic subtypes of CaP are known to be more aggressive and have recently garnered substantial attention. These histologic subtypes – namely, prostatic ductal adenocarcinoma (PDA), intraductal carcinoma of the prostate (IDC-P), and cribriform carcinoma of the prostate (CC-P) – typically exhibit distinct growth characteristics, genomic features, and unique oncologic outcomes. For example, PTEN mutations, which cause uncontrolled cell growth, are frequently present in IDC-P and CC-P. Germline mutations in homologous DNA recombination repair (HRR) genes (e.g., BRCA1, BRCA2, ATM, PALB2, and CHEK2) are discovered in 40% of patients with IDC-P, while only 9% of patients without ductal involvement had a germline mutation. CC-P is associated with deletions in common tumor suppressor genes, including PTEN, TP53, NKX3–1, MAP3K7, RB1, and CHD1. Evidence suggests abiraterone may be superior to docetaxel as a first-line treatment for patients with IDC-P. To address these and other critical pathological attributes, this review examines the molecular pathology, genetics, treatments, and oncologic outcomes associated with CC-P, PDA, and IDC-P with the objective of creating a comprehensive resource with a centralized repository of information on PDA, IDC-P, and CC-P. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
